Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IL-20, IL-21 and p40: potential biomarkers of treatment response for ustekinumab.

Acta dermato-venereologica - 27 Mar 2013

Gedebjerg Anne, Johansen Claus, Kragballe Knud, Iversen Lars

Abstract excerpt

Although biological drugs in psoriasis treatment show clinical efficacy, there are still a proportion of patients in whom little treatment response is obtained. The aim of this study was to identify molecular biomarkers for treatment response and to investigate the molecular effects of ustekinumab treatment of psoriasis. The mRNA expression of various genes in skin biopsies was analysed by quantitative polymerase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Biological Products

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biopsy

Share to Interleukin-12 Subunit p40

Share to Interleukin-21

Share to Interleukins

Share to Psoriasis

Source

Identifiers

PMID: 22930279
DOI: 10.2340/00015555-1440

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IL-20, IL-21 and p40: potential biomarkers of treatment response for ustekinumab.PMID 22930279Read ↗

miR-21-3p/IL-22 Axes Are Major Drivers of Psoriasis Pathogenesis by Modulating Keratinocytes Proliferation-Survival Balance and Inflammatory ResponseSemantic proximity Read ↗

Association between several immune response-related genes and the effectiveness of biological treatments in patients with moderate-to-severe psoriasis.Semantic proximity Read ↗

Modulation of inflammatory gene transcripts in psoriasis vulgaris: Differences between ustekinumab and etanerceptSemantic proximity Read ↗

Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status.Semantic proximity Read ↗

Biomolecular index of therapeutic efficacy in psoriasis treated with anti-TNF-α agents.Semantic proximity Read ↗

Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.Semantic proximity Read ↗

Insights into Therapeutic Response Prediction for Ustekinumab in Ulcerative Colitis Using an Ensemble Bioinformatics ApproachSemantic proximity Read ↗

IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.Semantic proximity Read ↗

Establishing a Generalizable Early Improvement Cutoff in Psoriasis Area and Severity Index for Outcome Prediction Across Systemic TreatmentsSemantic proximity Read ↗

microRNA-223 Expression during Flares in Patients with Generalized Pustular Psoriasis Is Regulated by Spesolimab TreatmentSemantic proximity Read ↗

Study of lncRNAs expression profile in the response to biological drugs in Psoriatic Arthritis: MEG3 could be a potential genomic biomarker of therapy efficacy.Semantic proximity Read ↗

Changes in <scp>mRNA</scp> expression precede changes in micro <scp>RNA</scp> expression in lesional psoriatic skin during treatment with adalimumabSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.